The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. That said, here are two value stocks trading at big discounts to their intrinsic values and one climbing an uphill battle.
Forward P/E Ratio: 10.8x
Originally spun off from General Electric in 2005 to provide business process services, Genpact (NYSE:G) is a global professional services firm that helps businesses transform their operations through digital technology, AI, and data analytics solutions.
Why Do We Think Twice About G?
-
Projected sales growth of 4.9% for the next 12 months suggests sluggish demand
-
Free cash flow margin dropped by 3.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Genpact is trading at $39.75 per share, or 10.8x forward P/E. Check out our free in-depth research report to learn more about why G doesn’t pass our bar.
Forward P/E Ratio: 14.2x
Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.
Why Are We Positive On AMGN?
-
14.6% annual revenue growth over the last two years surpassed the sector average as its offerings resonated with customers
-
Economies of scale give it some operating leverage when demand rises
-
Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
At $291.10 per share, Amgen trades at 14.2x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free for active Edge members.
Forward P/E Ratio: 10.3x
With roots dating back to 1955 and a pioneering role in money market funds, Federated Hermes (NYSE:FHI) is an investment management firm that offers a wide range of funds and strategies for institutional and individual investors.
Why Could FHI Be a Winner?
-
Performance over the past two years was boosted by share buybacks, which enabled its earnings per share to grow faster than its revenue
-
Market-beating return on equity illustrates that management has a knack for investing in profitable ventures